section name header

Pronunciation

soo-KRAL-fate

Classifications

Therapeutic Classification: antiulcer agents

Pharmacologic Classification: gi protectants

Indications

REMS

Unlabeled Uses:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Systemic absorption is minimal (<5%).

Distribution: Unknown.

Metabolism/Excretion: >90% is eliminated in the feces.

Half-life: 6–20 hr.

Time/Action Profile

(mucosal protectant effect)

ROUTEONSETPEAKDURATION
PO1–2 hrunknown6 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: pruritus, rash.

Endo: hyperglycemia (with suspension).

GI: constipation, diarrhea, dry mouth, gastric discomfort, indigestion, nausea.

Neuro: dizziness, drowsiness.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Route/Dosage

Treatment of Ulcers

Gastroesophageal Reflux

Stomatitis

Proctitis

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Carafate

Canadian Brand Names

Cytogard, Sulcrate, Sulcrate Plus